Linda Llewelyn Sells 6,442 Shares of Health Catalyst, Inc. (NASDAQ:HCAT) Stock

Health Catalyst, Inc. (NASDAQ:HCAT) insider Linda Llewelyn sold 6,442 shares of the business’s stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $7.88, for a total value of $50,762.96. Following the completion of the transaction, the insider now owns 98,702 shares in the company, valued at $777,771.76. This trade represents a 6.13 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Linda Llewelyn also recently made the following trade(s):

• On Tuesday, October 15th, Linda Llewelyn sold 1,324 shares of Health Catalyst stock. The shares were sold at an average price of $8.16, for a total value of $10,803.84.

Health Catalyst Stock Performance

Shares of HCAT stock opened at $7.27 on Thursday. The stock has a fifty day moving average price of $8.15 and a 200 day moving average price of $7.45. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.41 and a current ratio of 1.41. The stock has a market cap of $442.36 million, a PE ratio of -5.39 and a beta of 1.31. Health Catalyst, Inc. has a 1 year low of $5.42 and a 1 year high of $11.41.

Health Catalyst (NASDAQ:HCAT) last released its quarterly earnings results on Wednesday, November 6th. The company reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.03). The firm had revenue of $76.40 million for the quarter, compared to analyst estimates of $76.27 million. Health Catalyst had a negative return on equity of 7.51% and a negative net margin of 26.20%. The company’s quarterly revenue was up 3.5% compared to the same quarter last year. During the same period last year, the firm earned ($0.22) EPS. Sell-side analysts forecast that Health Catalyst, Inc. will post -0.33 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on HCAT shares. Piper Sandler reaffirmed an “overweight” rating and set a $12.00 price target (up from $11.00) on shares of Health Catalyst in a report on Tuesday, November 26th. Evercore ISI raised their target price on shares of Health Catalyst from $8.00 to $10.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 8th. Cantor Fitzgerald reiterated an “overweight” rating and set a $16.00 price target on shares of Health Catalyst in a research note on Friday, October 4th. Stephens raised their price objective on shares of Health Catalyst from $7.00 to $9.00 and gave the company an “equal weight” rating in a research report on Thursday, November 14th. Finally, JPMorgan Chase & Co. boosted their target price on Health Catalyst from $10.00 to $13.00 and gave the stock an “overweight” rating in a research report on Wednesday, September 4th. Three analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $11.79.

Institutional Trading of Health Catalyst

Large investors have recently modified their holdings of the business. Quest Partners LLC acquired a new position in shares of Health Catalyst during the 3rd quarter worth approximately $34,000. Nisa Investment Advisors LLC increased its position in Health Catalyst by 461.0% during the second quarter. Nisa Investment Advisors LLC now owns 6,367 shares of the company’s stock worth $41,000 after buying an additional 5,232 shares in the last quarter. Quarry LP raised its holdings in shares of Health Catalyst by 59.4% in the second quarter. Quarry LP now owns 7,002 shares of the company’s stock worth $45,000 after acquiring an additional 2,610 shares during the last quarter. nVerses Capital LLC purchased a new stake in shares of Health Catalyst in the third quarter valued at $59,000. Finally, Mackenzie Financial Corp acquired a new stake in shares of Health Catalyst during the second quarter valued at $70,000. 85.00% of the stock is currently owned by institutional investors and hedge funds.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.